Daiichi Sankyo's Ranbaxy open offer oversubscribed
This article was originally published in Scrip
Executive Summary
The number of fully paid-up shares tendered under Daiichi Sankyo's open offer for 20% of the voting capital of Ranbaxyhas exceeded the maximum number of 92,519,126. The Rs737 ($15.90) per share offer for the Rs5 shares ran from August 16th to September 4th and forms part of Daiichi Sankyo's planned acquisition of the Indian firm which is moving ahead despite US regulatory concerns about the quality of some of Ranbaxy's products. Daiichi Sankyo is acquiring a 34.8% stake from the Indian firm's founding family, also for Rs737 per share. The Japanese company said that offered shares were paid for or returned on September 19th and that its acceptance of these remained subject to certain regulatory approvals.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports